BY MARKETWIRE
-
Bavarian Nordic guides for lower revenue and operating profit in 2026
On Thursday early morning, the Danish vaccination firm launched its initial economic outcomes for 2025.
-
Novo Nordisk sees Chinese company announcing plans for semaglutide nasal spray
Shanghai Shiling Pharmaceutical’s goal is to have a product based on semaglutide through clinical trials in 2028.
-
Novo Nordisk boss calls on compounders to cooperate
” The compounders have a system that they can really utilize to the advantage of clients,” claims Mike Doustdar.
-
Eli Lilly builds massive stockpile of weight-loss pill ahead of FDA decision
The accumulation is most likely planned to satisfy anticipated need if the weight-loss tablet obtains FDA authorization in the 2nd quarter.
-
Lundbeck reports encouraging results with migraine candidate
Lundbeck’s migraine prospect Bocunebart was “usually well endured” in a stage IIb test, according to the pharmaceutical business.
-
Bavarian Nordic CFO on 2025 growth: Driven by core markets
According to the injection firm’s CFO, it is especially the German and United States markets that have actually driven development.
-
Novo Nordisk to produce Wegovy tablets in Ireland
Novo Nordisk prepares to broaden its manufacturing facility in Athlone, Ireland, to provide markets outside the United States.
-
Novo Nordisk plans to launch Wegovy vials
According to Novo Nordisk, the vials will originally be introduced on the United States market.
-
Bavarian Nordic guides for lower revenue and operating profit in 2026
On Thursday morning, the Danish vaccine company released its preliminary financial results for 2025.
-
AstraZeneca expects robust 2026, led by strong cancer drug demand
AstraZeneca anticipates a 2026 support of “mid-high single-digit sales development”.
